Compare GILT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GILT | ANL |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.0M | 998.8M |
| IPO Year | 1997 | 2022 |
| Metric | GILT | ANL |
|---|---|---|
| Price | $9.81 | $15.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $19.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 478.8K | 158.5K |
| Earning Date | 05-13-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.06 | $36.02 |
| Revenue Next Year | $11.72 | N/A |
| P/E Ratio | $42.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.37 | $0.88 |
| 52 Week High | $20.99 | $17.25 |
| Indicator | GILT | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 39.87 | 61.63 |
| Support Level | $9.37 | $12.45 |
| Resistance Level | $10.47 | $17.25 |
| Average True Range (ATR) | 0.37 | 1.08 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 30.91 | 85.62 |
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.